Michael R. Olin
Affiliations: | Neuroscience | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Oncology, Neuroscience Biology, ImmunologyGoogle:
"Michael Olin"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Raphael I, Mujeeb AA, Ampudia-Mesias E, et al. (2024) CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection. Biorxiv : the Preprint Server For Biology |
| Webb MJ, Sangsuwannukul T, van Vloten J, et al. (2024) Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Nature Communications. 15: 5442 |
| Webb MJ, Kottke T, Kendall BL, et al. (2023) Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses. Molecular Therapy Oncolytics. 29: 129-142 |
| Alghamri MS, Banerjee K, Mujeeb AA, et al. (2022) Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. Acs Nano |
| Ogino H, Taylor JW, Nejo T, et al. (2021) Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T-cell response in low-grade gliomas. The Journal of Clinical Investigation |
| Alghamri MS, McClellan BL, Hartlage MS, et al. (2021) Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology. 12: 680021 |
| Ampudia-Mesias E, Puerta-Martinez F, Bridges M, et al. (2021) CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics |
| Xiong Z, Ampudia Mesias E, Pluhar GE, et al. (2019) CD200 Checkpoint Reversal:A Novel Approach to Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Olin MR, Ampudia-Mesias E, Pennell CA, et al. (2019) Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma. Cancers. 11 |
| Moertel C, Pluhar GE, Ampudia-Mesias E, et al. (2019) IMMU-23. TARGETING THE CD200 CHECKPOINT TO ENHANCE IMMUNOTHERAPY FOR CNS TUMORS Neuro-Oncology. 21: ii97-ii98 |